Harrow relaunches Triesence in US
Click Here to Manage Email Alerts
Harrow announced the relaunch of Triesence, a preservative-free synthetic corticosteroid, according to a press release.
Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL is FDA approved for ocular inflammatory conditions unresponsive to topical corticosteroids as well as for visualization during vitrectomy. It was on the FDA drug shortage list for more than 5 years, and inventory has been depleted for 2 years, the release said.
“We are very excited to have brought Triesence back to the U.S. market, providing ophthalmologists access to a trusted FDA-approved product that has benefited millions of Americans,” Mark L. Baum, chairman and CEO of Harrow, said in the release. “Accomplishing this required rebuilding the entire Triesence supply chain and involved a global collaboration between Harrow and technical experts from our partners around the world.”
As Healio previously reported, Harrow acquired the U.S. commercial rights to Triesence in 2023.
Read more about
Click Here to Manage Email Alerts